inPractice® - Atazanavir

Special Considerations and Clinical Management of HIV in Patients With Substance Use Disorder

Author: Frederick L. Altice, MD (More Info)
Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
Last Reviewed: 2/5/20 (What's New)

Summary

Buprenorphine levels are significantly increased with either atazanavir 400 mg daily or atazanavir/ritonavir 300/100 mg daily^{[McCance-Katz 2007]}
Patients should be monitored for this effect when these drugs are given together and buprenorphine dose adjustment considered^{[FDA Atazanavir]}
Atazanavir should not be given unboosted with buprenorphine^{[FDA Atazanavir]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Drug-Drug Interactions, Initial Antiretroviral Therapy, IV Drug Use, Pharmacokinetics, Special Populations